EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 506 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Silence Speaks Volumes June 16, 2020 An integral part of research September 21, 2022 EMA Recommends Extension of Indications for Daratumumab June 10, 2021 Lo que deben saber las personas con cáncer de mama y... January 4, 2024 Load more HOT NEWS Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically... Specific Lung Cancer Screening and Treatment Policies Urgently Needed to Address... Radiation-Induced ‘Genomic Scars’ Associate with Poor Patient Outcome Physical Activity May Lessen the Effects of Chemobrain, Study Finds
